Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.
|Slideshows|July 9, 2021
COVID-19 Blues
Research confirms COVID-19’s negative impact on Americans’ mental health.
Advertisement
Advertisement
Related to this article
Ketamine or esketamine during C-section anesthesia lowers early postpartum depression symptom scores in trials, hinting at a new prevention approach under study.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
Advertisement
Advertisement
Trending on Psychiatric Times
1
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
2
Assessing Interventions for Insomnia in Peri- and Postmenopausal Women
3
Presenting Our November 2026 Theme: Emergency Psychiatry
4
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
5